Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$28,000.00
Oct 28, 2024
For-profit organization
IP Assist L3 : Intellectual Property Strategy Engagement
1023854
The project will support development of intellectual property capacity within the firm.
$8,207.00
Oct 7, 2023
For-profit organization
CIIP PDA – Feldan Bio Inc. – 2023-24
7455256 P013846001
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
$563,000.00
Sep 4, 2023
For-profit organization
Development of a treatment for mucus hypersecretion associated with pulmonary diseases by delivery of antisense oligonucleotides using Feldan Shuttle technology
$151,450.00
Nov 1, 2021
For-profit organization
Feasibility - Development of an Intracellular RNA Delivery Tool
981573
Development of an intracellular RNA delivery tool using the Feldan Shuttle, a novel peptide-based delivery platform.
$30,000.00
Jun 2, 2021
For-profit organization
YEP - Development of a method to treat Gorlin Syndrome using the Feldan Shuttle platform
973647
Development of a peptide-based technology that allows the delivery of various therapeutic compounds inside cells.
$30,000.00
May 31, 2021
For-profit organization
YEP - Hiring of a laboratory technician
973244
Development of a peptide-based technology that allows the delivery of various therapeutic compounds inside cells.
$32,515.00
Dec 20, 2020
For-profit organization
Innovation Assistance Program – Round 2.5
966497
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
$73,056.00
Jun 25, 2020
For-profit organization
Innovation Assistance Program – Round 2
962184
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
$60,984.00
Apr 1, 2020
For-profit organization
Innovation Assistance Program
949338
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
$600,000.00
Jan 18, 2018
For-profit organization
CIIP - Development of low-immunogenicity and high-activity NK cells for immuno-oncology applications
898129
Natural killer (NK) cells play a crucial role in the control of tumors, making them appealing for immunotherapy. Alongside Green Cross LabCell, Feldan aims to genetically modify NK cells to improve their potential for allogeneic engraftment and their cytotoxicity against tumors. This project will lead to the development of universal, off-the-shelf and hyperactive NK cells for immuno-oncology therapies.